IL-5 is induced locally in the lung and systemically in the circulation during allergic airways eosinophilic inflammation both in humans and experimental animals. However, the precise role of local and systemic IL-5 in the development of allergic airways eosinophilia remains to be elucidated. In our current study, we demonstrate that compared with their IL-5 ϩրϩ counterparts, IL-5 Ϫ / Ϫ mice lacked an IL-5 response both in the lung and peripheral blood, yet they released similar amounts of IL-4, eotaxin, and MIP-1 ␣ in the lung after ovalbumin (OVA) sensitization and challenge. At cellular levels, these mice failed to develop peripheral blood and airways eosinophilia while the responses of lymphocytes, neutrophils, and macrophages remained similar to those in IL-5 ϩրϩ mice. To dissect the relative role of local and systemic IL-5 in this model, we constructed a gene transfer vector expressing murine IL-5. Intramuscular IL-5 gene transfer to OVA-sensitized IL-5 Ϫ / Ϫ mice led to raised levels of IL-5 compartmentalized to the circulation and completely reconstituted airways eosinophilia upon OVA challenge, which was associated with reconstitution of eosinophilia in the bone marrow and peripheral blood. Significant airways eosinophilia was observed for at least 7 d in these mice. In contrast, intranasal IL-5 gene transfer, when rendered to give rise to a significant but compartmentalized level of transgene protein IL-5 in the lung, was unable to reconstitute airways eosinophilia in OVA-sensitized IL-5 Ϫ / Ϫ mice upon OVA-challenge, which was associated with a lack of eosinophilic responses in bone marrow and peripheral blood. Our findings thus provide unequivocal evidence that circulating but not local lung IL-5 is critically required for the development of allergic airways eosinophilia. These findings also provide the rationale for developing strategies to target circulating IL-5 and/or its receptors in bone marrow to effectively control asthmatic airways eosinophilia. ( J.
Introduction
Airways eosinophilic inflammation is a central pathologic feature of allergic asthma. The severity of asthma is correlated with the degree of airways eosinophilia (1, 2) . Eosinophils contribute to the pathogenesis of asthma by releasing a number of inflammatory mediators and toxic products including oxygen radicals and cationic proteins that can severely damage the airway epithelium and increase airway reactivity (1, 2) . Thus, understanding the molecular mechanisms underlying allergic airways eosinophilia has been a subject of intensive investigation. Eosinophils, like other types of leukocytes, originate from myeloid precursors in the bone marrow, but different from others, they are not present in abundance in the peripheral blood under resting conditions. It is believed that during immuneinflammatory responses, in addition to local tissue signals, a systemic signal(s) capable of eosinophil mobilization in the bone marrow is also required for the development of allergic airways eosinophilia. Among many soluble signals, IL-5 is considered to play an important role in the genesis of airways eosinophilia (1) (2) (3) (4) . Indeed, this cytokine has been found at raised levels both in the peripheral blood and lung tissue compartments in asthmatic patients (5) (6) (7) (8) . Similar findings were obtained from experimental models of allergic asthma where the peak circulating level of IL-5 preceded that in the lung after aerosol antigen challenge (9, 10) , suggesting the presence of antigen-specific lymphocytes both within and outside the respiratory mucosa. IL-5 is a well recognized eosinopoietic growth factor capable of stimulating eosinophil differentiation and maturation both in vitro and in vivo (2, 3, (11) (12) (13) . Furthermore, IL-5 has also been shown to be an eosinophil chemoattractant and a potent eosinophil survival enhancer (14) (15) (16) (17) . By using transgene approaches, we and others have shown that overexpression of IL-5 locally in the lung, as opposed to systemic overexpression (18) , induces marked airways eosinophilia (19, 20) or reconstitutes antigen-induced airways eosinophilia in IL-5 Ϫ / Ϫ mice (21) , and such induction of airways eosinophilia is always associated with systemic leakage of IL-5 and peripheral blood eosinophilia (19) (20) (21) . On the other hand, systemic administration of anti-IL-5 monoclonal antibodies, which abrogates both local and systemic IL-5, has been shown to inhibit antigen-induced airways eosinophilia in experimental models (22) (23) (24) . While these findings support an important role of IL-5 in the pathogenesis of allergic airways eosinophilia, the precise functional role of local and systemic IL-5 remains to be dissected.
In our current study, we have used two transgenic tools, IL-5 gene-deficient mice and an IL-5 gene transfer vector, to investigate the role of local and circulating IL-5 in the development of antigen-induced airways eosinophilia. Combined use of these genetic tools allowed us to reveal that circulating but not local lung IL-5 is critically required, via its effects on bone marrow and peripheral blood eosinophils, for the development of antigen-induced airways eosinophilia. Our findings suggest that circulating but not local IL-5 or its receptors in bone marrow represent a single, straightforward target for therapeutic strategies designed to effectively control asthmatic airways eosinophilia.
Methods
Mice and antigen-induced allergic airways inflammation. The generation and characterization of C57BL/6 IL-5 gene knock-out (IL-5 Ϫ / Ϫ ) and littermate control mice (IL-5 ϩ / ϩ ) have been described elsewhere (12) . Male or female mice were bred and maintained in the Level B pathogen-free facility at McMaster University Animal Quarter. Mice at the age of 8-12 wk were used. A mouse model of antigen-induced allergic airways inflammation was set up by ovalbumin (OVA) 1 sensitization and challenge as previously described by us (10) . In brief, mice were intraperitoneally sensitized twice, 5 d apart (day Ϫ 17 and day Ϫ 12) with 0.5 ml of a solution containing 8 g OVA (Sigma Chemical Co., St. Louis, MO) adsorbed overnight at 4 Њ C to 4 mg of aluminum hydroxide (Aldrich Chemical Company, Inc., Milwaukee, WI) in PBS (Fig. 1 ). Mice were then challenged at 12 d after the second sensitization with aerosolized OVA (day 0) (Fig. 1) .
Construction and preparation of recombinant replication-deficient adenoviral vector expressing mIL-5. A 600-bp EcoRI/HindIII fragment of full-length murine IL-5 cDNA was isolated from pEDFM-16 (a kind gift from Dr. Alistair Ramsay, Australian National University, Canberra, Australia) and ligated into the multicloning site of the shuttle vector pACCMV. The resultant pACCMV mIL-5 contained the mIL-5 cDNA positioned between a human cytomegalovirus promoter (CMV) and a SV40 splicing junction/polyA signal (polyA) in an orientation that allowed for the transcription of mIL-5 cDNA under control of the CMV promoter (Fig. 2) . This plasmid was cotransfected into 293 cells along with a plasmid pJM17, which contained the entire Ad5 DNA sequences with an insert in the E1 region (25) . By homologous recombination, the recombinant replication-deficient adenovirus Ad5E1pACCMVmIL-5 (AdIL-5) was rescued (Fig. 2) . AdIL-5 was characterized by Southern and Northern hybridizations. The production of IL-5 was determined by ELISA with the supernatant of A549 cells infected by AdIL-5 in vitro. Viral vectors were purified, titered, and stored as previously described (26) . A control viral vector Addl70-3 containing no transgene was used throughout the entire study.
Intramuscular or intranasal IL-5 gene transfer by AdIL-5. Mice were injected intramuscularly (i.m.) with AdIL-5 or Addl70-3 at 5 d before OVA challenge following a procedure we have previously described (27) . This approach was shown to result in marked transgene expression only in the muscle at the site of injection and active release of transgene protein into the circulation (27) . A dose of 0.1 ϫ 10 9 pfu of vector was diluted in a total of 100 l of PBS and injected i.m. into two hind legs of mice (two injection sites per leg, 25 l per site). In separate experiments, intranasal administration (i.n.) was performed to deliver transgene into the lung at 3 d before OVA challenge following a procedure we have previously described (28). We have previously demonstrated that this approach targets the transgene primarily to the bronchial epithelial cells and, to a lesser degree, to the alveolar epithelial cells and macrophages (28). A dose of 0.12 ϫ 10 9 pfu of vector was diluted in a total 30 l of PBS and delivered i.n. into appropriately anesthetized mice with a fine pipette tip (two administrations, 15 l each).
Preparation of blood smear, serum, bronchoalveolar lavage fluid and lung tissue. The mice were sacrificed at days 1, 3, or 7 after OVA challenge, and the peripheral blood, bronchoalveolar lavage (BAL), lung, and bone marrow were collected. Blood samples were obtained by retro-orbital bleeding. Total white blood cell numbers were determined after red blood cells lysis with RBC lysis buffer, and peripheral blood smears were prepared in duplicate with heparinized blood samples. Differential cell types were determined on blood smears by randomly counting 300-500 leukocytes. Serum was prepared from the whole blood by centrifugation at 12,000 rpm in a microcentrifuge for 10 min at 4 Њ C after incubation at 37 Њ C for 30 min and stored at Ϫ 20 Њ C until cytokine assays. BAL was performed as previously described (10, 28) . The mouse lung was lavaged with a total of 450 l of PBS in two separate aliquots (250 l and 200 l) through a polyethylene tube (Becton Dickinson, Sparks, MD) cannulated into the mouse trachea. Approximately 350 l of BAL was recovered by gentle massage of the lungs while retrieving. BAL fluids were then spun in a microcentrifuge at 5,000 rpm for 5 min, and supernatants were stored in Ϫ 20 Њ C until cytokine measurements. Cell pellets were resuspended in PBS and total cell numbers counted on a hemocytometer. Cytospins were prepared by cyto-centrifugation (Shandon Inc., Pittsburgh, PA). Differential cell counts were determined on Diff-Quik-stained (Baxter, McGaw Park, IL) cytospins by randomly counting ‫ف‬ 400 cells per slide. The lung was fixed by perfusion with 10% formalin. Lung sections were stained with hematoxylin and eosin.
Preparation of bone marrow cells. The femur was surgically removed and the connective tissues were carefully scraped off the bone. Both ends of the femur were opened using a sharp scalpel, and the marrow was perfused by repeatedly injecting 1.5 ml of 5A culture medium from the distal end of the femur, using a 3-ml syringe and a 23G needle. Bone marrow cells were dispersed by repeatedly moving the perfusate with bone marrow fragments in and out of the syringe, through the needle. Cytospins of dispersed bone marrow cells were prepared on APTEX coated glass slides. The slides were fixed using Diff-Quik fixative (Dade Diagnostics of P.R. Inc., Aguada, Puerto Rico), and stained using standard eosin staining techniques. The number of mature eosinophils was estimated by differential counting of 500-2,000 cells under a microscope with oil immersion.
Cytokine and IgE measurements. Murine IL-5 was measured by using an ELISA kit (Amersham, Buckinghamshire, UK). Murine IL-4, MIP-1 ␣ , and eotaxin were measured by using ELISA kits purchased from R&D Systems (Minneapolis, MN). The sensitivity of detection of these ELISA kits was 5 pg/ml for IL-5 and 2 to 3 pg/ml for IL-4, eotaxin, and MIP-1 ␣ . The level of OVA-specific IgE in serum was de-1. Abbreviations used in this paper: BAL, bronchoalveolar lavage; CMV, cytomegalovirus promoter; i.m., intramuscularly; i.n., intranasally; OVA, ovalbumin. ϪրϪ and IL-5 +/+ mice were sensitized twice intraperitoneally (i.p.) with 0.5 ml of aluminum OVA at days Ϫ17 and Ϫ12, then challenged by aerosolized OVA at day 0. The level of cellular responses in the lung, peripheral blood, and bone marrow and cytokine profiles were determined at days 1, 3, and 7, respectively. In separate experiments, OVA-sensitized IL-5 ϪրϪ mice were subjected to i.m. or i.n. delivery of AdIL-5 or Addl70-3 at days 5 and 3 before OVA challenge, respectively.
termined by using an antigen-capture ELISA method as previously described (10) .
Data analysis. Wherever applicable, results and differences were statistically analyzed by using a Minitab statistical software package (Minitab; State College, PA). An unpaired t test was used and the difference was considered statistically significant when P Յ 0.05.
Results

Lack of antigen-induced airways and peripheral blood eosinophilia in IL-5
Ϫ ր Ϫ mice. We characterized the difference in airways inflammation and peripheral blood responses between C57BL/6 IL-5 Ϫ / Ϫ and littermate control IL-5 ϩ / ϩ mice. OVA sensitization and aerosol challenge were carried out in these mice as previously described (10) (Fig. 1 ). Samples were collected and analyzed at days 1 and 3 after OVA challenge. We have previously demonstrated that cytokine and cellular responses peaked at days 1 and 3 in mice (10, 29) . The resting numbers of pulmonary macrophages in BAL fluids of naive IL-5 ϩ / ϩ and IL-5 Ϫ / Ϫ mice were similar (Fig. 3) . However, OVA challenge induced an approximately fivefold increase in total cell number in BAL from sensitized IL-5 ϩ / ϩ mice and only a threefold increase in sensitized IL-5 Ϫ / Ϫ mice at day 3. Approximately 50% of these cells in IL-5 ϩ / ϩ mouse lung were eosinophils. In contrast, there was only a marginally increased number of eosinophils found in BAL from IL-5 Ϫ / Ϫ mice (Fig. 3 ). Of note, the number of lymphocytes, neutrophils, and macrophages increased to a similar degree in both IL-5 Ϫ / Ϫ and IL-5 ϩ / ϩ mice. We then examined the inflammatory response in the peripheral blood. An increased level of peripheral blood eosinophilia in IL-5 ϩ / ϩ mice was observed after second OVA sensitization that further increased after OVA challenge (Table I). In contrast, there was a lack of peripheral blood eosinophilia in IL-5 Ϫ / Ϫ mice, thus in keeping with a lack of airways eosinophilia. The numbers of other cell types were comparable between IL-5 ϩ / ϩ and IL-5 Ϫ / Ϫ mice. While not surprisingly, there was no measurable IL-5 in BAL and serum from IL-5 Ϫ / Ϫ mice, and ‫ف‬ 260 and 390 pg/ml of IL-5 were detected in serum and BAL collected from IL-5 ϩ / ϩ mice at day 1 after OVA challenge, respectively (Fig. 4) .
Characterization of an adenoviral gene transfer vector expressing murine IL-5.
Having demonstrated a lack of IL-5 and eosinophilia in the peripheral blood and airways in OVA-sensitized IL-5 Ϫ / Ϫ but not IL-5 ϩ / ϩ mice upon antigen challenge, we set out to investigate the relative contribution of local and circulating IL-5 to the development of airways eosinophilia. A transgene approach was chosen to achieve IL-5 levels in a selected compartment in IL-5 Ϫ / Ϫ mice. This approach, in contrast to the use of recombinant protein, would allow us to achieve transient but prolonged levels of IL-5 in vivo (30) . To this end, a recombinant replication-deficient adenoviral gene transfer vector expressing murine IL-5 transgene was constructed (AdIL-5; Fig. 2 ). AdIL-5 was characterized by HindIII restriction digestion and Southern and Northern hybridization (data not shown). Upon infection with 10 pfu/cell of AdIL-5 but not with Addl70-3, A549 cells released 40.46 ng/ml of IL-5 in 48 h in vitro. To characterize AdIL-5 in vivo, four different doses of AdIL-5 were given i.m. to naive C57BL/6 mice, and sera were collected at 24 h and measured for murine IL-5 by ELISA. We have previously demonstrated that by this approach, transgene is localized to the muscle with active release of transgene protein into the circulation for a period of 10 to 12 d (27). The circulating level of IL-5 displayed a dose-dependent pattern ( Fig.  5 ) with ‫ف‬ 350 pg/ml being measured after delivery of a dose of 0.1 ϫ 10 9 pfu of AdIL-5, a level similar to that detected in IL-5 ϩ / ϩ mice during OVA-induced immune-inflammatory responses. This dose was thus chosen for i.m. delivery in IL-5 Ϫ / Ϫ mice in the following experiments. In a kinetic study, the level of IL-5 in the circulation was observed to peak at day 1, decrease but still remain significant by day 5, and markedly decline close to background by day 8 after i.m. IL-5 gene transfer (not shown).
Reconstitution of antigen-induced airways eosinophilia by intramuscular IL-5 gene transfer in IL-5
Ϫ / Ϫ mice. We then investigated whether circulating IL-5, in the absence of local IL-5 in the lung, was sufficient to reconstitute antigen-induced airways eosinophilia in antigen-sensitized/challenged IL-5 Ϫ / Ϫ mice by using AdIL-5. Intramuscular gene transfer to naive IL-5 Ϫ / Ϫ mice of a dose of 0.1 ϫ 10 9 pfu AdIL-5 led to highly compartmentalized IL-5 levels in the circulation with 350 pg/ml measured in serum but little in BAL fluids at the peak time (Fig. 6 ). This dose of AdIL-5 or control vector Addl70-3 was then injected i.m. to OVA-sensitized IL-5 Ϫ / Ϫ mice at day Ϫ5 (Fig. 1) . Delivery of AdIL-5 at day Ϫ5 was to ensure that the bone marrow eosinophil progenitors be stimulated by IL-5 before OVA challenge. Our previous study has suggested the involvement of an early IL-5 response in eosinophil responses in the bone marrow and peripheral blood before the onset of airways eosinophilia by OVA aerosol challenge (10). On examination of cellular responses in the BAL at day 3 after OVA challenge, we observed a lack of airways eosinophilia in IL-5
Ϫ/Ϫ mice receiving no vector or i.m. Addl70-3 control vector. In contrast, airways eosinophilia was fully reconstituted in the lung of IL-5 Ϫ/Ϫ mice receiving i.m. delivery of AdIL-5, compared with that in IL-5 ϩ/ϩ mice (Fig. 7 A) . The number of other leukocyte types was similar among various groups. To examine whether such antigen-induced airways eosinophilia could persist without IL-5 present in the local lung tissue, cellular profiles in BAL obtained at 7 d after OVA challenge were analyzed. The number of eosinophils still remained markedly increased in the lung of IL-5 Ϫ/Ϫ mice receiving AdIL-5 (Fig. 7 B) . This level of lung eosinophilia, albeit somewhat lower, was still comparable with that in the lung of IL-5 ϩ/ϩ mice. We next examined histopathology of lung tissues obtained at day 3 after OVA challenge. In accord with BAL cytologic analysis, while there were similar degrees of perivascular and peribronchial accumulation of lymphocytes, neutrophils, and monocytes in the lung of both IL-5 ϩ/ϩ and IL-5 Ϫ/Ϫ mice, there were few eosinophils seen in the lung of IL-5 Ϫ/Ϫ mice, in sharp contrast to significant accumulation of eosinophils in the lung of IL-5 ϩ/ϩ mice (Fig. 8, a and b) . However, intramuscular IL-5 gene transfer but not Addl70-3 administration fully reconstituted airways eosinophilia in lung tissues of IL-5 Ϫ/Ϫ mice (Fig. 8, c and d) . gene transfer, similar to that in IL-5 ϩ/ϩ mice (Fig. 9 A) . Accompanied with eosinophilic responses in the bone marrow was a peripheral blood eosinophilia in IL-5 Ϫ/Ϫ mice receiving IL-5 i.m. gene transfer, the level of which also increased to that in IL-5 ϩ/ϩ mice (Fig. 9 B) . These were in contrast to the lack of peripheral blood eosinophilia in IL-5 Ϫ/Ϫ mice without or with i.m. delivery of Addl70-3.
Similar levels of IL-4 and chemokines eotaxin and MIP-1␣ in the lung of IL-5
+/+ and IL-5 ϪրϪ mice. These results have thus far indicated that circulating IL-5, via its effects on bone marrow and peripheral blood eosinophils, is a systemic signal required for the development of antigen-induced airways eosinophilia, which can occur in the absence of local levels of IL-5 in the lung. It is believed, however, that certain local tissue signals are required for circulating eosinophils to migrate across the vasculature into the airways. In this regard, IL-4, in addition to its other activities, enhances eosinophil adhesion to the endothelium by upregulating VCAM-1 expression (31), and C-C chemokines eotaxin and MIP-1␣ have chemotactic effects on eosinophils (32, 33) . We measured the content of IL-4, eotaxin, and MIP-1␣ in BAL fluids collected at day 1 after OVA challenge from IL- 
Lack of reconstitution of antigen-induced airways eosinophilia following compartmentalized intrapulmonary IL-5 gene transfer in IL-5
Ϫ/Ϫ mice. Our findings have thus far strongly suggested that if only present locally in the lung but not in the circulation, IL-5 cannot reconstitute airways eosinophilia in IL-5 Ϫ/Ϫ mice. To demonstrate this, we delivered a dose of 0.12 ϫ 10 9 pfu of AdIL-5 i.n. into the lung of IL-5 Ϫ/Ϫ mice at day Ϫ3 (Fig. 1) . We have previously shown that by this approach the level in BAL of transgene protein peaks at ‫ف‬ day 4 (28); thus, delivering AdIL-5 3 d before OVA challenge would ϪրϪ mice with i.n. AdIL-5 delivery (f). There is a marked infiltration of mononuclear cells with few eosinophils seen in Fig. 8, a, c, e , and f. In contrast, marked airways eosinophilia is seen in Fig. 8, b and (Table III) . This level of compartmentalized IL-5 transgene protein in the lung failed to reconstitute antigen-induced airways eosinophilia as shown by BAL cellular analysis (Fig. 10) . The lack of eosinophilic responses under such conditions was further supported by histologic examination (Fig. 8, e and f) . In keeping with these findings, there were minimal increases in the number of eosinophils in the bone marrow and peripheral blood (data not shown).
Discussion
In this study, we demonstrated that, in contrast to their IL-5 ϩ/ϩ counterparts, the lack of IL-5 response both in the lung and BAL fluids were collected at day 1 after OVA-challenge. IL-4, eotaxin and MIP-1␣ were measured by specific ELISA. Data represent meanϮSEM from IL-5 Ϫ/Ϫ OVA (n ϭ 3), IL-5 Ϫ/Ϫ OVA Add170-3 (n ϭ 3), IL-5 Ϫ/Ϫ OVA AdIL-5 (n ϭ 3) and IL-5 ϩ/ϩ OVA (n ϭ 4) mice. There is no statistically significant difference between treatments. The levels of these cytokines in BAL from naive IL-5 Ϫ/Ϫ or IL-5 ϩ/ϩ mice were under or close to the assay detection limit. BAL fluids and sera were collected at day 4 post-i.n. delivery of AdIL-5 or control vector Addl70-3 and measured for IL-5 content by ELISA. Results are expressed as meanϮSEM. The limit of assay detection is 5 pg/ml.
peripheral blood in IL-5 Ϫ/Ϫ mice resulted in a lack of peripheral and airways eosinophilia in response to antigen sensitization and challenge, whereas the response of lymphocytes, neutrophils, and macrophages, and the level of IL-4 and chemokines in the lung were not markedly weakened in these mice. Circulating IL-5 by intramuscular IL-5 gene transfer to antigen-sensitized IL-5 Ϫ/Ϫ mice reconstituted eosinophilia not only in the bone marrow and peripheral blood but also in the airway upon antigen challenge. In contrast, local compartmentalized IL-5 achieved by intrapulmonary IL-5 gene transfer to these mice was unable to reconstitute airways eosinophilia, which was associated with a failure in reconstituting bone marrow and peripheral blood eosinophilia. These findings indicate a critical role of circulating IL-5 in the development of antigen-induced airways eosinophilia and suggest that, contrary to previously thought, local lung IL-5 plays a relatively less important role in the process of eosinophil accumulation in the airways.
IL-5, GM-CSF, and IL-3 are members of the hematopoietic growth factor family. Different from GM-CSF and IL-3, IL-5 has restricted biologic effects, primarily on eosinophils and eosinophil progenitors (2, 3). IL-5 has been shown to stimulate the differentiation of eosinophil progenitor cells in vitro and in systemic IL-5 transgenic mice (11, 13) . In contrast to marked peripheral blood eosinophilia in IL-5 transgenic mice, GM-CSF transgenic mice developed only mild peripheral blood eosinophilia, together with markedly increased numbers of neutrophils and monocytes (34) . However, IL-5 is not merely an eosinopoietic growth factor since a wealth of in vitro evidence has suggested that it is also an eosinophil chemoattractant and survival factor (14) (15) (16) (17) . Indeed, the level of IL-5 is increased in the peripheral blood and local lung tissue both in asthmatic patients and experimental models of asthmatic inflammation (5) (6) (7) (8) (9) (10) . And recently, IL-5, but not IL-3, receptor expression on CD34 + progenitors and the number of eosinophil progenitor cells in the bone marrow have been found markedly increased in mild asthmatic patients upon local lung allergen challenge (35, 36) . Thus, the role of IL-5 in the pathogenesis of allergic asthma has been thought to be mediated through its effects not only on eosinophil differentiation in the bone marrow but also on eosinophil influx and survival locally in the lung (1) (2) (3) (4) 17) . This notion appears to be supported by further experimental observations. Systemic administration of anti-IL-5 monoclonal antibodies inhibited antigen-induced airways eosinophilia (22) (23) (24) ; IL-5 Ϫ/Ϫ mice failed to mount antigen-induced airways eosinophilia unless an IL-5 gene transfer vector was repeatedly intranasally delivered before and during antigen challenge (21) ; overexpression of IL-5 locally in the lung, either by delivering repeated large doses of recombinant IL-5 (37), or gene transfer vectors (19), or in lung-specific IL-5 transgenic mice (20) , induced airways eosinophilia. However, systemically delivered antibodies will abrogate not only circulating IL-5 but also local lung IL-5. High levels of local overexpression of IL-5 result in not only higher than physiologic levels of IL-5 protein in the lung, but also spillovers of IL-5 into the circulation; induction of airways eosinophilia was invariably associated with an increased number of peripheral blood eosinophils (19-21). On the other hand, since IL-5 was shown to be chemotactic to eosinophils in vitro only when present at much higher concentrations compared with classic eosinophil chemoattractants (17) , it is very likely that the influx of eosinophils into the airways occurs as a result of eosinophil chemotaxis to transgenic levels of IL-5 in the lung, which may not represent a physiologic functional aspect of IL-5 during immune-inflammatory responses. Hence, the relative role of local and systemic IL-5 in allergic airways eosinophilia remains to be clarified.
To dissect the role of local and systemic IL-5 in the pathogenesis of allergic airways eosinophilia, we first examined the cellular and cytokine responses in OVA-sensitized and challenged IL-5-deficient mice. Consistent with a previous study (21) , we found a lack of airways and peripheral blood eosinophilia in IL-5 Ϫ/Ϫ mice. However, in contrast to that study, we found similar responses of other leukocyte subsets including lymphocytes, neutrophils, and macrophages both in BAL and lung tissues. Such discrepancies are likely due to differences in the protocol for sensitization and challenge. Upon examination of cytokines, we found significantly increased levels of IL-5 in BAL and peripheral blood in IL-5 ϩ/ϩ mice but not in IL-5 Ϫ/Ϫ mice upon OVA challenge. In contrast, the level of another Th2 cytokine IL-4 and CC chemokines eotaxin and MIP-1␣ in the lung was similar between IL-5 ϩ/ϩ and IL-5 Ϫ/Ϫ mice, thus likely explaining the similar extent of airways inflammatory responses of lymphocytes, neutrophils, and macrophages. Of interest, although not statistically significant, there appeared lower levels of eotaxin in the lung of mice with airways eosinophilia (IL-5 ϩ/ϩ OVA or IL-5 Ϫ/Ϫ OVA AdIL-5 i.m.) as compared with those in mice without airways eosinophilia. This may not reflect a lower production but rather suggests a greater consumption of eotaxin in the lung by infiltrating eosinophils. These findings, to our knowledge, represent the first experimental evidence that the lack of IL-5 and airways eosinophilia has little effect on the level of cytokines and influx of leukocytes other than eosinophils in the lung during allergic airways inflammation.
We then investigated the role of local and systemic IL-5 in allergic airways eosinophilia by using an IL-5 transgene ap- proach in sensitized IL-5 Ϫ/Ϫ mice. Intramuscular delivery of an IL-5 gene transfer vector led to raised IL-5 levels compartmentalized to the peripheral blood compartment and completely reconstituted airways eosinophilia in IL-5 Ϫ/Ϫ mice after OVA challenge. Of importance, such a reconstitution of airways eosinophilia was associated with a restored eosinophilic response in the bone marrow and peripheral blood. The magnitude of airways eosinophilia was identical or even slightly higher than that seen in IL-5 ϩ/ϩ mice at day 3 after OVA challenge (8 d after i.m. IL-5 gene transfer). It is noteworthy that circulating levels of transgene protein IL-5 in IL-5 Ϫ/Ϫ mice during the period from OVA challenge (day 0) to death (day 3) had declined towards the baseline (5-8 d after i.m. gene transfer). This suggests that the eosinophil priming or mobilizing effect by systemic IL-5 before OVA-aerosol challenge is of critical importance in the onset of airways eosinophilia. Indeed, we observed an increase in the number of peripheral blood eosinophils in OVA-sensitized IL-5 ϩ/ϩ mice before OVA challenge. Furthermore, it suggests that high circulating levels of IL-5 that emerge and peak around day 1 after OVA challenge in IL-5 ϩ/ϩ mice are not required for the peak airways eosinophilic response (day 3). On the other hand, our finding that full reconstitution of airways eosinophilia in IL-5 Ϫ/Ϫ mice by i.m. IL-5 gene transfer took place in the absence of lung tissue IL-5, indicates that local lung IL-5 is not required for the development of a full-blown antigen-induced airways eosinophilia. Such dissociability of antigen-induced airways eosinophilia from significant tissue levels of IL-5 in the lung is further supported by our observation that there was still marked airways eosinophilia in IL-5 Ϫ/Ϫ mice receiving i.m. IL-5 gene transfer 7 d after OVA challenge. This latter finding also suggests a significant role of molecules other than IL-5 in the perpetuation of airways eosinophilia during asthmatic inflammation. While it remains to be determined whether i.m. IL-5 gene transfer concurrently reconstituted airways hyperreactivity in IL-5 Ϫ/Ϫ mice, a recent study in a different model system has suggested that systemic IL-5, in the presence of specific IgE, is also involved in enhanced airways reactivity (38) . With establishment of the critical role of systemic IL-5 in airways eosinophilia, we explored the potential mechanisms within the lung by which eosinophils migrated into the airways despite the absence of local IL-5. We found that the level of IL-4, eotaxin, and MIP-1␣ was not compromised in the lung of antigen-challenged IL-5 Ϫ/Ϫ mice, thus indicating that other eosinophil-active cytokines are fully capable of mounting airways eosinophilia in the absence of local IL-5. We have recently found that IL-4, together with TNF␣, is required for VCAM-1 upregulation on pulmonary vasculature, which is in turn required for the development of allergic airways eosinophilia (39) . Eosinophil chemokines including eotaxin and MIP-1␣ have been shown involved in eosinophil chemotaxis in the lung during allergic airways inflammation (32, 33, (40) (41) (42) . In addition, we have previously shown that there is a small but significant level of GM-CSF being induced in the lung during allergic airways inflammation (10) . It is thus possible that GM-CSF implements many biologic activities that IL-5 is capable of in this model. The requirement of such coordination between systemic IL-5 and local lung cytokines such as eotaxin for the onset of airways eosinophilia is also supported by recent findings from skin models (43) (44) (45) .
Thus, we have demonstrated that circulatory but not local lung IL-5 is critically required for the development of antigeninduced airways eosinophilia via its effect on bone marrow and peripheral blood eosinophils. On the other hand, local cytokine signals in the absence of IL-5 are sufficient to set up a stage for airway eosinophil accumulation to take place. While these findings shall not dismiss the possible potentiating/activating activities by local lung IL-5, together with other cytokines, on accumulating eosinophils in asthmatic airways tissues, they provide important rationale for developing strategies to target circulating, rather than local, IL-5, or its receptors in BM to effectively control asthmatic airways eosinophilia, particularly in steroid-resistant asthmatics.
